Coca Ramona, Moisin Andrei, Coca Rafaela, Diter Atasie, Racheriu Mihaela, Tanasescu Denisa, Popa Carmen, Cerghedean-Florea Maria-Emilia, Boicean Adrian, Tanasescu Ciprian
Clinical Medical Department, Faculty of General Medicine, "Lucian Blaga" University of Sibiu, Str. Lucian Blaga nr. 2A, 550169 Sibiu, Romania.
Department of Oncology, Sibiu County Emergency Clinical Hospital, B-dul Corneliu Coposu nr. 2-4, 550245 Sibiu, Romania.
Life (Basel). 2024 Aug 18;14(8):1025. doi: 10.3390/life14081025.
Breast cancer is one of the most common forms of neoplasia worldwide. The purpose of our observational study was to evaluate the status of HER2 overexpression among new cases of breast neoplasia with an impact on the natural history of breast cancer disease and therapeutic personalization according to staging. This study included 45 breast cancer patients which have an overexpression of HER2 through the mutation of the EGFR-ERBB2 receptor. Immunohistochemical staining was performed on sections of formalin-fixed paraffin-embedded breast tissue. The patients were evaluated demographically and therapeutically in all stages. The post-surgical histopathological examination revealed complete pathological responses in 19 patients and pathological responses with residual disease either at the tumor level or lymphatic or both variants in a percentage of 44% (15 cases). The disease-free interval (DFI) under anti-HER2 therapy was recorded in 41 patients, representing 91% of the study group. Anti-HER2 therapy in any therapeutic stage has shown increased efficiency in blocking these tyrosine kinase receptors, evidenced by the high percentage of complete pathological responses, as well as the considerable percentage (47%) of complete remissions and stationary disease, in relation to the HER2-positive patient group.
乳腺癌是全球最常见的肿瘤形成形式之一。我们的观察性研究目的是评估乳腺肿瘤新发病例中HER2过表达的状况，及其对乳腺癌疾病自然史和根据分期进行治疗个体化的影响。本研究纳入了45例通过EGFR-ERBB2受体突变而出现HER2过表达的乳腺癌患者。对福尔马林固定石蜡包埋的乳腺组织切片进行免疫组织化学染色。对所有分期的患者进行人口统计学和治疗方面的评估。术后组织病理学检查显示，19例患者出现完全病理缓解，15例（占44%）患者在肿瘤层面或淋巴管或两者均出现有残留疾病的病理反应。41例患者记录了抗HER2治疗下的无病生存期（DFI），占研究组的91%。在任何治疗阶段，抗HER2治疗均显示出在阻断这些酪氨酸激酶受体方面效率提高，这体现在完全病理缓解的高比例，以及相对于HER2阳性患者组而言相当比例（47%）的完全缓解和疾病稳定。
